

Mauro Bernardi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3021854/publications.pdf>

Version: 2024-02-01

130
papers

18,596
citations

32410

55
h-index

15698

129
g-index

148
all docs

148
docs citations

148
times ranked

11712
citing authors

#	ARTICLE	IF	CITATIONS
1	Alcohol-Related Liver Disease in the Covid-19 Era: Position Paper of the Italian Society on Alcohol (SIA). Digestive Diseases and Sciences, 2022, 67, 1975-1986.	1.1	7
2	Towards a new definition of decompensated cirrhosis. Journal of Hepatology, 2022, 76, 202-207.	1.8	66
3	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 74, 1097-1108.	1.8	149
4	Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF. Journal of Hepatology, 2021, 74, 1117-1131.	1.8	45
5	The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. Journal of Hepatology, 2021, 74, 670-685.	1.8	204
6	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. Journal of Hepatology, 2021, 74, 340-349.	1.8	38
7	Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications. Hepatology, 2021, 74, 2058-2073.	3.6	45
8	Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. Journal of Hepatology, 2021, 75, S49-S66.	1.8	146
9	Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. Journal of Clinical Medicine, 2021, 10, 4590.	1.0	4
10	AISF-SIMTI position paper on the appropriate use of albumin in patients with liver cirrhosis: a 2020 update. Blood Transfusion, 2021, 19, 9-13.	0.3	4
11	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2020, 5, 31-41.	3.7	75
12	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. Journal of Hepatology, 2020, 72, 688-701.	1.8	223
13	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	1.8	282
14	Prognostic Role of Bacterial and Fungal Infections in Patients With Liver Cirrhosis With and Without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study. Open Forum Infectious Diseases, 2020, 7, ofaa453.	0.4	7
15	Terlipressin May Decrease In-Hospital Mortality of Cirrhotic Patients with Acute Gastrointestinal Bleeding and Renal Dysfunction: A Retrospective Multicenter Observational Study. Advances in Therapy, 2020, 37, 4396-4413.	1.3	9
16	Long-term albumin administration is not futile in patients with cirrhosis and uncomplicated ascites not normalizing serum albumin concentration with treatment. Journal of Hepatology, 2020, 73, S738.	1.8	0
17	<p>Albumin Administration is Efficacious in the Management of Patients with Cirrhosis: A Systematic Review of the Literature<p>. Hepatic Medicine: Evidence and Research, 2020, Volume 12, 153-172.	0.9	15
18	Albumin in decompensated cirrhosis: new concepts and perspectives. Gut, 2020, 69, 1127-1138.	6.1	190

#	ARTICLE	IF	CITATIONS
19	Albumin: Indications in chronic liver disease. United European Gastroenterology Journal, 2020, 8, 528-535.	1.6	9
20	Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation. JHEP Reports, 2019, 1, 270-277.	2.6	12
21	PS-083-Serum albumin concentration as guide for long-term albumin treatment in patients with cirrhosis and uncomplicated ascites: Lessons from the ANSWER study. Journal of Hepatology, 2019, 70, e53.	1.8	5
22	QT interval corrected for heart rate is not associated with mortality in patients with cirrhosis and ascites. Scandinavian Journal of Gastroenterology, 2019, 54, 1376-1378.	0.6	2
23	Reply to: "Prophylaxis of spontaneous bacterial peritonitis: is there still room for quinolones?" Journal of Hepatology, 2019, 70, 1028-1030.	1.8	2
24	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. Liver International, 2019, 39, 1478-1489.	1.9	41
25	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. Gastroenterology, 2019, 157, 149-162.	0.6	178
26	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. Frontiers in Immunology, 2019, 10, 476.	2.2	134
27	Development and Validation of a Scoring System That Includes Corrected QT Interval for Risk Analysis of Patients With Cirrhosis and Gastrointestinal Bleeding. Clinical Gastroenterology and Hepatology, 2019, 17, 1388-1397.e1.	2.4	16
28	Reply. Hepatology, 2019, 69, 2713-2714.	3.6	1
29	Long-term albumin administration in patients with decompensated cirrhosis. It is time for a reappraisal. Liver International, 2019, 39, 45-48.	1.9	9
30	Diagnosis and Treatment of Alcohol Use Disorder in Patients With End-Stage Alcoholic Liver Disease. Hepatology, 2019, 70, 410-417.	3.6	37
31	Extended Infusion of β -Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study. Clinical Infectious Diseases, 2019, 69, 1731-1739.	2.9	29
32	Pro: The Role of Albumin in Pre-Liver Transplant Management. Liver Transplantation, 2019, 25, 128-134.	1.3	9
33	Orchestration of Tryptophan-Kynurenine Pathway, Acute Decompensation, and Acute-on-Chronic Liver Failure in Cirrhosis. Hepatology, 2019, 69, 1686-1701.	3.6	80
34	Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis. Aging, 2019, 11, 8502-8525.	1.4	26
35	The use of human albumin in patients with cirrhosis: a European survey. Expert Review of Gastroenterology and Hepatology, 2018, 12, 625-632.	1.4	14
36	EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology, 2018, 69, 406-460.	1.8	1,762

#	ARTICLE	IF	CITATIONS
37	Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1792-1800.e3.	2.4	127
38	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 859-871.	0.9	38
39	Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections. <i>Gut</i> , 2018, 67, 1892-1899.	6.1	98
40	Accesses for alcohol intoxication to the emergency department and the risk of re-hospitalization: An observational retrospective study. <i>Addictive Behaviors</i> , 2018, 77, 1-6.	1.7	11
41	Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 403-414.	1.2	45
42	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. <i>Hepatology</i> , 2018, 67, 1784-1796.	3.6	93
43	Questions in the design of ANSWER – Authors' reply. <i>Lancet, The</i> , 2018, 392, 1623-1624.	6.3	0
44	Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study. <i>BMC Gastroenterology</i> , 2018, 18, 177.	0.8	23
45	Approach and management of dysnatremias in cirrhosis. <i>Hepatology International</i> , 2018, 12, 487-499.	1.9	14
46	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018, 391, 2417-2429.	6.3	345
47	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. <i>Hepatology</i> , 2018, 68, 1232-1244.	3.6	26
48	Novel perspectives in the management of decompensated cirrhosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 753-764.	8.2	60
49	Mortality risk in a cohort of Italian alcoholic individuals treated for alcohol dependence. <i>Drug and Alcohol Review</i> , 2017, 36, 186-191.	1.1	4
50	Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis. <i>Hepatology</i> , 2017, 66, 1232-1241.	3.6	72
51	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 423-433.	1.9	46
52	The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study. <i>Liver International</i> , 2017, 37, 71-79.	1.9	57
53	A Brief Up-Date of the Use of Sodium Oxybate for the Treatment of Alcohol Use Disorder. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 290.	1.2	25
54	Does the evidence support a survival benefit of albumin infusion in patients with cirrhosis undergoing large-volume paracentesis?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 11, 1-2.	1.4	14

#	ARTICLE	IF	CITATIONS
55	Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. <i>Hepatology</i> , 2016, 64, 1249-1264.	3.6	550
56	Transient elastography in healthy subjects and factors influencing liver stiffness in non-alcoholic fatty liver disease: An Italian community-based population study. <i>Digestive and Liver Disease</i> , 2016, 48, 1357-1363.	0.4	22
57	Albumin Homodimers in Patients with Cirrhosis: Clinical and Prognostic Relevance of a Novel Identified Structural Alteration of the Molecule. <i>Scientific Reports</i> , 2016, 6, 35987.	1.6	35
58	AISF-SIMTI Position Paper: The appropriate use of albumin in patients with liver cirrhosis. <i>Digestive and Liver Disease</i> , 2016, 48, 4-15.	0.4	24
59	Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: A case series. <i>Journal of Psychopharmacology</i> , 2016, 30, 402-409.	2.0	7
60	AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis. <i>Blood Transfusion</i> , 2016, 14, 8-22.	0.3	13
61	Ischaemia-modified albumin: a marker of bacterial infection in hospitalized patients with cirrhosis. <i>Liver International</i> , 2015, 35, 2425-2432.	1.9	20
62	Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. <i>Hepatology</i> , 2015, 62, 243-252.	3.6	493
63	Hyponatremia in Patients with Cirrhosis of the Liver. <i>Journal of Clinical Medicine</i> , 2015, 4, 85-101.	1.0	23
64	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <i>Gut</i> , 2015, 64, 531-537.	6.1	405
65	Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. <i>Hepatology</i> , 2015, 62, 567-574.	3.6	283
66	Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. <i>Journal of Hepatology</i> , 2015, 62, 968-974.	1.8	571
67	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2015, 62, 831-840.	1.8	289
68	Mass spectrometric characterization of human serum albumin dimer: A new potential biomarker in chronic liver diseases. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 112, 169-175.	1.4	29
69	Chronic hepatitis B: Are we close to a cure?. <i>Digestive and Liver Disease</i> , 2015, 47, 836-841.	0.4	17
70	Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. <i>Journal of Hepatology</i> , 2015, 63, 1272-1284.	1.8	463
71	Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: A phase I clinical trial. <i>Digestive and Liver Disease</i> , 2015, 47, 1059-1066.	0.4	22
72	Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis. <i>Gut</i> , 2015, 64, 1616-1622.	6.1	86

#	ARTICLE	IF	CITATIONS
73	Hepatitis C virus recurrence after liver transplantation: A 10-year evaluation. <i>World Journal of Gastroenterology</i> , 2015, 21, 3912.	1.4	6
74	Posttranscriptional changes of serum albumin: Clinical and prognostic significance in hospitalized patients with cirrhosis. <i>Hepatology</i> , 2014, 60, 1851-1860.	3.6	135
75	Hyponatremia influences the outcome of patients with acute-on-chronic liver failure: an analysis of the CANONIC study. <i>Critical Care</i> , 2014, 18, 700.	2.5	41
76	Reply. <i>Hepatology</i> , 2014, 60, 1443-1445.	3.6	2
77	Pharmacological management of alcohol dependence: From mono-therapy to pharmacogenetics and beyond. <i>European Neuropsychopharmacology</i> , 2014, 24, 181-191.	0.3	30
78	Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). <i>Journal of Hepatology</i> , 2014, 60, 275-281.	1.8	259
79	Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. <i>Journal of Hepatology</i> , 2014, 60, 1310-1324.	1.8	685
80	Sodium oxybate in maintaining alcohol abstinence in alcoholic patients according to Lesch typologies: A pilot study. <i>Journal of Psychopharmacology</i> , 2014, 28, 23-30.	2.0	18
81	Role of Human Albumin in the Management of Complications of Liver Cirrhosis. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, 302-311.	0.4	84
82	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2014, 61, 1038-1047.	1.8	741
83	Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. <i>Journal of Hepatology</i> , 2014, 61, 51-58.	1.8	104
84	Increase of ribavirin dose improves sustained virological response in HCV-genotype 1 patients with a partial response to peg-interferon and ribavirin. <i>Annals of Hepatology</i> , 2014, 13, 196-203.	0.6	1
85	Clinical indications for the albumin use: Still a controversial issue. <i>European Journal of Internal Medicine</i> , 2013, 24, 721-728.	1.0	133
86	Effective albumin concentration and cirrhosis mortality: From concept to reality. <i>Journal of Hepatology</i> , 2013, 59, 918-920.	1.8	32
87	Dorsal acoustic windows may ameliorate liver ultrasound in patients with chronic liver disease and meteorism/obesity/ascites. <i>Journal of Medical Ultrasonics (2001)</i> , 2013, 40, 399-408.	0.6	1
88	Interactions of the heart and the liver. <i>European Heart Journal</i> , 2013, 34, 2804-2811.	1.0	346
89	Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 1426-1437.e9.	0.6	2,211
90	Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications. <i>Hepatology</i> , 2013, 58, 1836-1846.	3.6	327

#	ARTICLE	IF	CITATIONS
91	Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites. <i>Liver International</i> , 2013, 33, 16-23.	1.9	63
92	Cirrhotic cardiomyopathy. <i>Clinical Liver Disease</i> , 2013, 2, 99-101.	1.0	8
93	Sodium oxybate to treat alcohol dependence: 20 years of clinical experience. <i>Addiction Biology</i> , 2013, 18, 901-903.	1.4	4
94	Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. <i>Gut</i> , 2012, 61, 108-116.	6.1	121
95	QT interval prolongation in liver cirrhosis: innocent bystander or serious threat?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 57-66.	1.4	86
96	Human albumin in the management of complications of liver cirrhosis. <i>Critical Care</i> , 2012, 16, 211.	2.5	63
97	QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. <i>Liver International</i> , 2012, 32, 1510-1515.	1.9	48
98	Albumin infusion in patients undergoing large-volume paracentesis: A meta-analysis of randomized trials. <i>Hepatology</i> , 2012, 55, 1172-1181.	3.6	285
99	Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation. <i>Digestive and Liver Disease</i> , 2011, 43, 242-245.	0.4	25
100	The MELD score in patients awaiting liver transplant: Strengths and weaknesses. <i>Journal of Hepatology</i> , 2011, 54, 1297-1306.	1.8	140
101	Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity. <i>European Neuropsychopharmacology</i> , 2011, 21, 450-456.	0.3	26
102	How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. <i>World Journal of Gastroenterology</i> , 2011, 17, 3479.	1.4	26
103	Spontaneous bacterial peritonitis: from pathophysiology to prevention. <i>Internal and Emergency Medicine</i> , 2010, 5, 37-44.	1.0	29
104	Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: Which is the winner?. <i>Liver Transplantation</i> , 2010, 16, 964-973.	1.3	50
105	Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. <i>Liver International</i> , 2010, 30, 937-947.	1.9	161
106	Optimum use of diuretics in managing ascites in patients with cirrhosis. <i>Gut</i> , 2010, 59, 10-11.	6.1	18
107	Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. <i>Journal of Hepatology</i> , 2010, 53, 283-290.	1.8	78
108	Cannabinoid Type 1 Receptor Antagonism Delays Ascites Formation in Rats With Cirrhosis. <i>Gastroenterology</i> , 2009, 137, 341-349.	0.6	46

#	ARTICLE	IF	CITATIONS
109	Gamma Hydroxybutyric Acid (GHB) for the Treatment of Alcohol Dependence: A Review. <i>International Journal of Environmental Research and Public Health</i> , 2009, 6, 1917-1929.	1.2	64
110	Effect of chronic β_2 -blockade on QT interval in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 2008, 48, 415-421.	1.8	83
111	Muscle circulation contributes to hyperdynamic circulatory syndrome in advanced cirrhosis. <i>Journal of Hepatology</i> , 2008, 48, 559-566.	1.8	10
112	Is ceftriaxone better than norfloxacin for prophylaxis of infection in patients with advanced cirrhosis and hemorrhage?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, 190-191.	1.7	2
113	Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: An open randomised comparative study. <i>European Neuropsychopharmacology</i> , 2007, 17, 781-789.	0.3	53
114	QT Interval Correction in Patients with Cirrhosis. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 18, 77-82.	0.8	67
115	Cardiac electrophysiological abnormalities in patients with cirrhosis. <i>Journal of Hepatology</i> , 2006, 44, 994-1002.	1.8	141
116	Effect of Liver Transplantation on Tuftsin Activity and Phagocytic Activity of Neutrophil Granulocytes in Patients with Liver Cirrhosis. <i>International Archives of Allergy and Immunology</i> , 2005, 137, 258-262.	0.9	7
117	The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. <i>Hepatology</i> , 2003, 38, 258-266.	3.6	744
118	QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. <i>Journal of Hepatology</i> , 2003, 38, 461-467.	1.8	88
119	Systemic and regional hemodynamics in pre-ascitic cirrhosis: effects of posture. <i>Journal of Hepatology</i> , 2003, 39, 502-508.	1.8	20
120	Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: Effect of the nutritional status. <i>Hepatology</i> , 2001, 33, 808-815.	3.6	138
121	Effect of increasing dose of interferon on the evolution of hepatitis C virus 1b quasispecies. , 2000, 60, 133-138.		7
122	Starvation Impairs Antioxidant Defense in Fatty Livers of Rats Fed A Choline-Deficient Diet. <i>Journal of Nutrition</i> , 2000, 130, 2131-2136.	1.3	94
123	Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites. <i>Hepatology</i> , 1999, 30, 1387-1392.	3.6	79
124	Investigation into the Use of Alcohol at Thermal Spas: Can a Spa Represent a Place for Primary Prevention?. <i>Alcoholism: Clinical and Experimental Research</i> , 1998, 22, 1072-1073.	1.4	1
125	Q-T interval prolongation in cirrhosis: Prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. <i>Hepatology</i> , 1998, 27, 28-34.	3.6	356
126	Hyponatremia in cirrhosis: From pathogenesis to treatment. <i>Hepatology</i> , 1998, 28, 851-864.	3.6	237

#	ARTICLE	IF	CITATIONS
127	Anthropometric characteristics of healthy Italian nonagenarians and centenarians. <i>British Journal of Nutrition</i> , 1997, 77, 9-17.	1.2	32
128	Prognostic indicators in patients with cirrhosis and hepatocellular carcinoma undergoing surgical resection. <i>Journal of Surgical Oncology</i> , 1993, 53, 67-69.	0.8	6
129	The hemodynamic status of preascitic cirrhosis: An evaluation under steady-state conditions and after postural change. <i>Hepatology</i> , 1992, 16, 341-346.	3.6	87
130	Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. <i>Hepatology</i> , 1988, 8, 1151-1157.	3.6	1,513